Fusion Proteins Recruiting Hsp70 to Reduce Tau Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively address the misfolding and aggregation of tau proteins, which are central to neurodegenerative diseases such as Alzheimer's, leading to neuronal degeneration and cognitive impairments, with unclear molecular mechanisms and limited treatment options.
Innovation Solution
Development of fusion proteins comprising a J domain and a tau-binding domain that recruit the cell's innate Hsp70-mediated chaperone mechanism to specifically reduce tau-mediated protein aggregation, utilizing a J domain and a tau-binding domain with high affinity for tau proteins to inhibit aggregation and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat Alzheimer's disease, then symptomatic relief may be achieved, but the misfolding and aggregation of tau proteins cannot be effectively addressed
Solution Approach 1:
The patent employs Hsp70 chaperone proteins as intermediaries to mediate the recognition and resolution of misfolded tau proteins. The Hsp70 chaperone acts as a molecular mediator that binds to aggregated tau proteins through its substrate binding domain and facilitates their refolding or degradation, thereby addressing the fundamental mechanism of tau pathology that current therapies fail to target.
Solution Approach 2:
The invention leverages the cell's innate Hsp70-mediated chaperone mechanism to self-correct tau protein misfolding. By enhancing the natural protein quality control system rather than introducing foreign therapeutic agents, the therapy enables the cellular machinery to autonomously recognize, bind, and resolve misfolded tau proteins, providing a self-sustaining therapeutic effect.
2Reliability
If fusion proteins comprising J domain and tau-binding domain are developed, then specific reduction of tau-mediated protein aggregation can be achieved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The fusion protein is segmented into distinct functional domains: an N-terminal Hsp70 binding domain (J domain) that recruits the chaperone mechanism, and a C-terminal tau-binding domain that provides specificity for tau protein recognition. This segmentation allows each domain to independently perform its specialized function while being part of a unified therapeutic molecule, achieving both specificity and efficacy without excessive complexity.
Solution Approach 2:
The invention merges two separate functional elements—the Hsp70 binding capability and the tau-specific binding capability—into a single fusion protein molecule. This combining of functions into one integrated therapeutic agent simplifies the overall therapeutic structure compared to using separate molecules or complex multi-component systems, while maintaining the ability to specifically reduce tau aggregation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion proteins effectively reduce the levels of hyperphosphorylated tau proteins, potentially mitigating the progression of tau-related disorders by enhancing protein folding and clearance, offering a novel approach to treating neurodegenerative diseases.
Implementation Method 1
the cell's innate Hsp70-mediated chaperone mechanism to specifically reduce tau-mediated protein aggregation
Data Source
AI summary
A novel class of fusion proteins to recruit a cell's innate chaperone mechanism, specifically the Hsp70-mediated system, to specifically reduce tau-mediated protein aggregation and associated proteopathies is disclosed.